Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: Scientific Reports 12 (2022), 11846, 1-9
- Event
-
Veröffentlichung
- (where)
-
Münster
- (who)
-
Universitäts- und Landesbibliothek Münster
- (when)
-
2023
- Creator
-
Schlack, Katrin
Seitzer, Konstantin Egon
Wüstmann, Neele
Humberg, Verena
Grundmann, Norbert
Steinestel, Julie
Tiedje, Dorothee
Rahbar, Kambiz
Krabbe, Laura-Maria
Bögemann, Martin
Schrader, Andres Jan
Bernemann, Christof
- DOI
-
10.17879/88988470916
- URN
-
urn:nbn:de:hbz:6-58988676858
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
25.03.2025, 1:43 PM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Schlack, Katrin
- Seitzer, Konstantin Egon
- Wüstmann, Neele
- Humberg, Verena
- Grundmann, Norbert
- Steinestel, Julie
- Tiedje, Dorothee
- Rahbar, Kambiz
- Krabbe, Laura-Maria
- Bögemann, Martin
- Schrader, Andres Jan
- Bernemann, Christof
- Universitäts- und Landesbibliothek Münster
Time of origin
- 2023
Other Objects (12)
Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients
Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving 177Lu-PSMA-617 Radioligand Therapy
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer
Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer
Treatment-Related Healthcare Costs of Metastatic Castration-Resistant Prostate Cancer in Germany: A Claims Data Study
Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
Pain Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with 223Ra : PARABO, a Prospective, Noninterventional Study
Outcome of 177Lu-PSMA-617 radioligand therapy in chemo-refractory patients with metastatic castration-resistant early-onset prostate cancer
EMT-specific circulating micro RNAs and circulating tumor cells in metastatic breast cancer
Salvage radioligand therapy with repeated cycles of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer with diffuse bone marrow involvement
Treatment with a 177Lutetium-radiolabeled ligand targeting prostate-specific membrane antigen in metastatic castration-resistant prostate cancer: toxicity, efficacy and survival.
Assessing the quality of life of patients with metastatic castration-resistant prostate cancer with bone metastases receiving [223Ra]RaCl2 therapy
Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients
Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving 177Lu-PSMA-617 Radioligand Therapy
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer
Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer
Treatment-Related Healthcare Costs of Metastatic Castration-Resistant Prostate Cancer in Germany: A Claims Data Study
Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
Pain Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with 223Ra : PARABO, a Prospective, Noninterventional Study
Outcome of 177Lu-PSMA-617 radioligand therapy in chemo-refractory patients with metastatic castration-resistant early-onset prostate cancer
EMT-specific circulating micro RNAs and circulating tumor cells in metastatic breast cancer
Salvage radioligand therapy with repeated cycles of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer with diffuse bone marrow involvement
Treatment with a 177Lutetium-radiolabeled ligand targeting prostate-specific membrane antigen in metastatic castration-resistant prostate cancer: toxicity, efficacy and survival.
Assessing the quality of life of patients with metastatic castration-resistant prostate cancer with bone metastases receiving [223Ra]RaCl2 therapy
Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients
Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving 177Lu-PSMA-617 Radioligand Therapy
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer
Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer
Treatment-Related Healthcare Costs of Metastatic Castration-Resistant Prostate Cancer in Germany: A Claims Data Study
Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
Pain Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with 223Ra : PARABO, a Prospective, Noninterventional Study
Outcome of 177Lu-PSMA-617 radioligand therapy in chemo-refractory patients with metastatic castration-resistant early-onset prostate cancer
EMT-specific circulating micro RNAs and circulating tumor cells in metastatic breast cancer
Salvage radioligand therapy with repeated cycles of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer with diffuse bone marrow involvement
Treatment with a 177Lutetium-radiolabeled ligand targeting prostate-specific membrane antigen in metastatic castration-resistant prostate cancer: toxicity, efficacy and survival.